LabCorp® Announces the Availability of Affymetrix-Based Whole Genome Microarrays
Complete the form below to unlock access to ALL audio articles.
Laboratory Corporation of America® Holdings (LabCorp®) has announced the availability of an ultra high-density microarray, Affymetrix based technology (Whole-Genome Sampling Analysis). The offering continues the numerous recent advances in LabCorp’s clinical genetics laboratory diagnostics.
In 2005, LabCorp first offered the comparative genomic hybridization (CGH) based microarray diagnostics which focused on mental retardation and developmental delay. This targeted testing underscored the need for higher density whole genome coverage.
The Affymetrix-based technology provides analysis of DNA copy number changes – identifying deletions, gene amplifications and loss of heterozygosity (LOH).
“This new testing will offer unparalleled resolution for the detection of the etiology of mental retardation, developmental delay, autism and other clinically significant changes and underscores LabCorp’s commitment to providing physicians and patients the highest quality services to meet their clinical needs,” said Myla Lai-Goldman, M.D., Executive Vice President, Chief Scientific Officer and Medical Director of LabCorp.
